2PR3 | date | ![]() |
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
authors | |||||||||||||||
compound | source | ||||||||||||||
symmetry |
| ||||||||||||||
crystal cell |
| ||||||||||||||
method | X-Ray Diffraction | resolution | |||||||||||||
ligand | 237, CA BindingDB | enzyme |
| ||||||||||||
Gene Ontology ![]() |
| ||||||||||||||
Primary reference | Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors., Van Huis CA, Bigge CF, Casimiro-Garcia A, Cody WL, Dudley DA, Filipski KJ, Heemstra RJ, Kohrt JT, Narasimhan LS, Schaum RP, Zhang E, Bryant JW, Haarer S, Janiczek N, Leadley RJ Jr, McClanahan T, Thomas Peterson J, Welch KM, Edmunds JJ, Chem Biol Drug Des. 2007 Jun;69(6):444-50. PMID:17581239 |
Data retrieval |
![]() |
View 2PR3 in 3D |
![]() |
Structure-derived information |
Sequence-derived information |
OCA© by Jaime Prilusky, 1996-2014,2022,2024 Bioinformatics Unit Weizmann Institute of Science |